Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 9/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.35 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488847 | 0.86 | PTGS2 (0.42) | CNR1PTGS2 | |
| SCHEMBL544317 | 0.81 | CNR1 (0.49) | MRGPRX4NOTUMCNR1 | |
| SCHEMBL544918 | 0.81 | PAICS (0.40) | MRGPRX4CNR1 | |
| SCHEMBL913482 | 0.80 | CNR1 (0.40) | MRGPRX4NOTUMCNR1 | |
| SCHEMBL545109 | 0.79 | HSD17B14 (0.40) | NOTUMCNR1HSD17B14EGFR | |
| SCHEMBL544339 | 0.78 | FFAR1 (0.44) | CNR1SLC6A15 | |
| SCHEMBL27751941 | 0.76 | EGFR (0.37) | NOTUMCNR1HSD17B14EGFR | |
| SCHEMBL19835545 | 0.72 | SLC6A3 (0.51) | CNR1 | |
| SCHEMBL5363014 | 0.72 | CNR1 (0.65) | CNR1 | |
| SCHEMBL912835 | 0.72 | NOTUM (0.40) | MRGPRX4NOTUMCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653276-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI (FR) | 2013-09-26 | — | — | US | disclosed |
| US-8466292-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | MRGPRX4 120/4885NOTUM 2370/4885CNR1 65/4885 |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | MRGPRX4 120/4885NOTUM 2370/4885CNR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.